Citadel Advisors
CUE icon

Citadel Advisors’s Cue Biopharma CUE Stock Holding History

Citadel Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-423
Closed -$2.92K – 13854
2026
Q1 		$2.92K Buy
+423
New +$3.95K ﹤0.01% 12829
2025
Q2 		– Sell
-47
Closed -$1.27K – 12913
2025
Q1 		$1.27K Buy
47
+7
+18% +$260 ﹤0.01% 14150
2024
Q4 		$1.31K Sell
40
-47
-54% -$1.77K ﹤0.01% 14204
2024
Q3 		$1.97K Sell
87
-283
-76% -$6.13K ﹤0.01% 13792
2024
Q2 		$13.8K Buy
370
+160
+76% +$7.91K ﹤0.01% 12923
2024
Q1 		$11.9K Buy
210
+163
+347% +$11.5K ﹤0.01% 13383
2023
Q4 		$3.7K Sell
47
-200
-81% -$14.3K ﹤0.01% 13568
2023
Q3 		$17K Buy
247
+30
+14% +$2.93K ﹤0.01% 12747
2023
Q2 		$23.7K Buy
217
+134
+161% +$15.7K ﹤0.01% 12585
2023
Q1 		$8.93K Buy
83
+3
+4% +$286 ﹤0.01% 13620
2022
Q4 		$6.84K Buy
+80
New +$7.32K ﹤0.01% 13879
2022
Q3 		– Sell
-513
Closed -$38K – 12759
2022
Q2 		$38K Sell
513
-70
-12% -$8.19K ﹤0.01% 12090
2022
Q1 		$85K Buy
583
+16
+3% +$3.39K ﹤0.01% 12426
2021
Q4 		$192K Buy
567
+210
+59% +$81.2K ﹤0.01% 11900
2021
Q3 		$156K Sell
357
-1,990
-85% -$694K ﹤0.01% 12331
2021
Q2 		$820K Sell
2,347
-2,233
-49% -$866K ﹤0.01% 8879
2021
Q1 		$1.68M Buy
4,580
+107
+2% +$44K ﹤0.01% 6833
2020
Q4 		$1.68M Buy
+4,473
New +$1.79M ﹤0.01% 5737

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Citadel Advisors's CUE Position: Q2 2026 in Review

Citadel Advisors opened a new position in Cue Biopharma (CUE) in Q2 2026: 25,633 shares worth $809K. The stake represents ﹤0.01% of the portfolio and ranks #8727 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CUE as recently as Q2 2024.

Citadel Advisors first reported a position in CUE in Q1 2020 and has held it in 16 quarters since. The position peaked at $6.69M in Q2 2020. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Citadel Advisors held 25,633 shares of Cue Biopharma worth $809K as of Q2 2026.
  • Cue Biopharma was a new Citadel Advisors position in Q2 2026.
  • Cue Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8727 holding.
  • Citadel Advisors first reported a position in Cue Biopharma in Q1 2020 and has held it in 16 quarters since.
  • Citadel Advisors's Cue Biopharma position peaked at $6.69M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.